Mr. Kalyanasundaram Subramanian ('Kal'), (born in February, 1954) joined Sun Pharmaceutical Industries Limited ('Sun') in January 2010 after 22 years with GSK. Kal is a Chemistry graduate and a Chartered Accountant from India with 37 years of experience. He has over three decades of experience in the pharmaceutical industry. Mr. Kal's career in the pharma industry began when he joined Burroughs Wellcome, in New Zealand as Commercial Advisor in 1988. In his long association with Burroughs Wellcome (which was acquired by Glaxo to become GlaxoWellcome and finally GlaxoSmithKline) he has held various leadership positions including Vice President, Head of Classic Brands Business of Emerging Markets; Area Director South Asia & Managing Director, GSK India; Managing Director – GlaxoWellcome, Singapore (Singapore, Indochina & Myanmar) & Commercial Director - Burroughs Wellcome, New Zealand. In 2010, Kal joined Sun as the CEO and Director-India and Emerging Markets. He was instrumental in Merck (MSD) and Sun collaboration and spearheaded opening of Sun operations in few important markets such as Japan, MENA. In 2012, Kal moved to Taro Pharmaceutical Industries Ltd. ('Taro'), USA, a subsidiary of Sun, to assume responsibility of Taro's operations in North America. In January 2017, Kal moved back to India to manage India and EM regions of Sun and has also been appointed as the CEO & whole-time Director of Sun Pharma Laboratories Limited, a wholly-owned subsidiary of Sun.

Healthcare